相似文献
1
Correction to: Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases.
BMC Cancer. 2018 Dec 24;18(1):1288. doi: 10.1186/s12885-018-5215-7.
2
Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases.
BMC Cancer. 2018 Dec 3;18(1):1198. doi: 10.1186/s12885-018-5110-2.
3
Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study.
BMC Cancer. 2019 Sep 9;19(1):896. doi: 10.1186/s12885-019-6107-1.
4
Intracranial Responses to Afatinib at Different Doses in Patients With EGFR-mutated Non-small-cell Lung Carcinoma and Brain Metastases.
Clin Lung Cancer. 2019 May;20(3):e274-e283. doi: 10.1016/j.cllc.2019.02.009. Epub 2019 Feb 26.
5
Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study.
BMC Cancer. 2019 Oct 26;19(1):1006. doi: 10.1186/s12885-019-6140-0.
6
Afatinib-refractory brain metastases from EGFR-mutant non-small-cell lung cancer successfully controlled with erlotinib: a case report.
Anticancer Drugs. 2016 Mar;27(3):251-3. doi: 10.1097/CAD.0000000000000317.
7
Response to afatinib in treatment-naïve patients with advanced mutant epidermal growth factor receptor lung adenocarcinoma with brain metastases.
Expert Rev Anticancer Ther. 2018 Jan;18(1):81-89. doi: 10.1080/14737140.2018.1409623. Epub 2017 Dec 2.
8
First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases.
J Thorac Oncol. 2016 Mar;11(3):380-90. doi: 10.1016/j.jtho.2015.11.014. Epub 2016 Jan 25.
9
A phase I trial of afatinib and bevacizumab in chemo-naïve patients with advanced non-small-cell lung cancer harboring EGFR mutations: Okayama Lung Cancer Study Group Trial 1404.
Lung Cancer. 2018 Jan;115:103-108. doi: 10.1016/j.lungcan.2017.11.025. Epub 2017 Nov 28.
10
Afatinib and lung cancer.
Expert Rev Anticancer Ther. 2014 Dec;14(12):1391-406. doi: 10.1586/14737140.2014.983083.
引用本文的文献
1
Management of diarrhea induced by EGFR-TKIs in advanced lung adenocarcinoma.
Ther Adv Med Oncol. 2023 Aug 24;15:17588359231192396. doi: 10.1177/17588359231192396. eCollection 2023.
2
Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence.
Adv Ther. 2021 May;38(5):2038-2053. doi: 10.1007/s12325-021-01696-9. Epub 2021 Mar 17.
3
First-line afatinib for the treatment of mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting.
Ther Adv Med Oncol. 2019 Apr 15;11:1758835919836374. doi: 10.1177/1758835919836374. eCollection 2019.
本文引用的文献
1
Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases.
BMC Cancer. 2018 Dec 3;18(1):1198. doi: 10.1186/s12885-018-5110-2.
Zotero 插件